783 related articles for article (PubMed ID: 33388422)
1. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.
Hu X; Wang J; Chu M; Liu Y; Wang ZW; Zhu X
Mol Ther; 2021 Mar; 29(3):908-919. PubMed ID: 33388422
[TBL] [Abstract][Full Text] [Related]
2. Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy.
Jiang Y; Hong K; Zhao Y; Xu K
Front Immunol; 2023; 14():1228200. PubMed ID: 37415977
[TBL] [Abstract][Full Text] [Related]
3. Programmed Death Ligand 1 Regulatory Crosstalk with Ubiquitination and Deubiquitination: Implications in Cancer Immunotherapy.
Kim SB; Hwang S; Cha JY; Lee HJ
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474186
[TBL] [Abstract][Full Text] [Related]
4. The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint.
Wang Q; Lin W; Tang X; Li S; Guo L; Lin Y; Kwok HF
Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186904
[TBL] [Abstract][Full Text] [Related]
5. Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy.
Ni JM; Ni AP
Chin Med Sci J; 2018 Sep; 33(3):174-182. PubMed ID: 30266108
[TBL] [Abstract][Full Text] [Related]
6. Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.
Shen X; Zhang L; Li J; Li Y; Wang Y; Xu ZX
Front Immunol; 2019; 10():1337. PubMed ID: 31258527
[TBL] [Abstract][Full Text] [Related]
7. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
Ai L; Xu A; Xu J
Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy.
Bocanegra A; Blanco E; Fernandez-Hinojal G; Arasanz H; Chocarro L; Zuazo M; Morente P; Vera R; Escors D; Kochan G
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824655
[TBL] [Abstract][Full Text] [Related]
9. PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy.
Ren X; Wang L; Liu L; Liu J
Front Immunol; 2024; 15():1392546. PubMed ID: 38638430
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
[TBL] [Abstract][Full Text] [Related]
11. Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer.
Kowalski A; Malinowska K; Olszewski J; Zielińska-Bliźniewska H
Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356594
[TBL] [Abstract][Full Text] [Related]
12. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy.
Zhai W; Zhou X; Zhai M; Li W; Ran Y; Sun Y; Du J; Zhao W; Xing L; Qi Y; Gao Y
Sci China Life Sci; 2021 Apr; 64(4):548-562. PubMed ID: 32737851
[TBL] [Abstract][Full Text] [Related]
13. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.
Sun Z; Mai H; Xue C; Fan Z; Li J; Chen H; Huo N; Kang X; Tang C; Fang L; Zhao H; Han Y; Sun C; Peng H; Du Y; Yang J; Du N; Xu X
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040417
[TBL] [Abstract][Full Text] [Related]
14. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment.
Hudson K; Cross N; Jordan-Mahy N; Leyland R
Front Immunol; 2020; 11():568931. PubMed ID: 33193345
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
Wang Y; Ma R; Liu F; Lee SA; Zhang L
Front Immunol; 2018; 9():374. PubMed ID: 29556232
[TBL] [Abstract][Full Text] [Related]
16. [Regulation of PD-L1 posttranslational modification and its application progress in tumor immunotherapy].
Su Y; Wang Q; Ru Y; Dong J; Li X; Zhang Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Nov; 38(11):1036-1043. PubMed ID: 36328434
[TBL] [Abstract][Full Text] [Related]
17. Generation, secretion and degradation of cancer immunotherapy target PD-L1.
Shen DD; Bi YP; Pang JR; Zhao LJ; Zhao LF; Gao Y; Wang B; Liu HM; Liu Y; Wang N; Zheng YC; Liu HM
Cell Mol Life Sci; 2022 Jul; 79(8):413. PubMed ID: 35819633
[TBL] [Abstract][Full Text] [Related]
18. PD-1/PD-L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity.
Hosseinzadeh R; Feizisani F; Shomali N; Abdelbasset WK; Hemmatzadeh M; Gholizadeh Navashenaq J; Jadidi-Niaragh F; Bokov DO; Janebifam M; Mohammadi H
IUBMB Life; 2021 Nov; 73(11):1293-1306. PubMed ID: 34538007
[TBL] [Abstract][Full Text] [Related]
19. Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway.
Wakabayashi G; Lee YC; Luh F; Kuo CN; Chang WC; Yen Y
J Biomed Sci; 2019 Dec; 26(1):96. PubMed ID: 31801525
[TBL] [Abstract][Full Text] [Related]
20. Regulation of programmed death-ligand 1 expression in response to DNA damage in cancer cells: Implications for precision medicine.
Sato H; Jeggo PA; Shibata A
Cancer Sci; 2019 Nov; 110(11):3415-3423. PubMed ID: 31513320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
